Safety and efficacy of prednisone versus placebo in short-term prevention of episodic cluster headache: a multicentre, double-blind, randomised controlled trial

医学 丛集性头痛 强的松 安慰剂 整群随机对照试验 期限(时间) 双盲 随机对照试验 儿科 物理疗法 内科学 替代医学 偏头痛 量子力学 物理 病理
作者
Mark Obermann,Steffen Nägel,Claudia Ose,Nilüfer Sonuc,André Scherag,Peter Storch,Charly Gaul,Andreas Böger,Torsten Kraya,Jan‐Peter Jansen,Andreas M. Straube,Tobias M. Freilinger,Holger Kaube,Tim Patrick Jürgens,Hans‐Christoph Diener,Zaza Katsarava,Christoph Kleinschnitz,Dagny Holle
出处
期刊:Lancet Neurology [Elsevier BV]
卷期号:20 (1): 29-37 被引量:78
标识
DOI:10.1016/s1474-4422(20)30363-x
摘要

Summary Background Prednisone is commonly used for initial short-term therapy of episodic cluster headaches before preventive medication such as verapamil becomes effective, but this strategy has not been tested in large randomised trials. We aimed to access the safety and efficacy of this treatment approach. Methods This study was a multicentre, randomised, double-blind, placebo-controlled trial done in ten specialised headache centres in Germany. Patients with episodic cluster headaches who were aged between 18 and 65 years and within a current pain episode for not more than 30 days, received 100 mg oral prednisone for 5 days followed by tapering of 20 mg every 3 days, or matching placebo (17 days total exposure). All patients received oral verapamil for long-term prevention, starting with 40 mg three times daily and increasing to 120 mg three times daily by day 19; patients then continued with verapamil 120 mg throughout the study. Randomisation was computer-generated at a 1:1 ratio by use of an interactive web-response system, with stratification according to age, sex, and participating site. Participants, investigators, and those assessing outcomes were unaware of treatment allocation. The primary endpoint was the mean number of attacks within the first week of treatment with prednisone compared with placebo. An attack was defined as a unilateral headache with moderate-to-severe intensity of at least five on a numerical rating scale. All efficacy and safety analyses were done in the modified intention-to-treat (mITT) population, which consisted of all patients who had been randomly assigned to a trial group and received at least one dose of prednisone or placebo. The study was stopped early due to slow recruitment and expired funding. The study was registered with EudraCT (2011–006204–13) and with the German Clinical Trials Register (DRK4716). Findings Between April 5, 2013, and Jan 11, 2018, 118 patients were enrolled in the study. Two patients dropped out immediately and 116 patients were randomly assigned (57 patients to prednisone and 59 patients to placebo); 109 patients were included in the mITT analysis (53 patients assigned to prednisone and 56 patients assigned to placebo). Participants in the prednisone group had a mean of 7·1 (SD 6·5) attacks within the first week compared with 9·5 (6·0) attacks in the placebo group (difference −2·4 attacks, 95% CI −4·8 to −0·03; p=0·002). Two serious adverse events occurred, both in the placebo group (inguinal hernia and severe deterioration of cluster headache). A total of 270 adverse events were observed: in the prednisone group, 37 (71%) of 52 patients reported 135 adverse events (most common were headache, palpitations, dizziness, and nausea) and in the placebo group, 39 (71%) of 55 patients had 135 adverse events (most common were nausea, dizziness, and headache). Interpretation Oral prednisone was an effective short-term preventive therapy in our population of patients with episodic cluster headache. Our findings support the use of prednisone as a first-line treatment in parallel to the up-titration of verapamil, although the efficacy of prednisone alongside other long-term prevention requires additional investigation. Funding German Federal Ministry for Education and Research.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
未来森林发布了新的文献求助10
刚刚
三十三完成签到,获得积分10
刚刚
刚刚
一投就中完成签到,获得积分10
1秒前
2秒前
yinyin发布了新的文献求助10
3秒前
hhhhhuo发布了新的文献求助10
4秒前
希望天下0贩的0的应助被初景采纳,获得10
5秒前
补药学习完成签到,获得积分10
5秒前
6秒前
6秒前
7秒前
坚定丹亦完成签到,获得积分10
8秒前
9秒前
An完成签到,获得积分10
10秒前
小川完成签到,获得积分10
11秒前
XPR发布了新的文献求助10
11秒前
11秒前
打打的应助被O基米德采纳,获得10
12秒前
12秒前
妮妮发布了新的文献求助10
12秒前
hhhhhuo完成签到,获得积分10
13秒前
ykk完成签到 ,获得积分10
13秒前
Liszt完成签到,获得积分10
13秒前
学术小白完成签到,获得积分10
14秒前
14秒前
LL完成签到,获得积分10
15秒前
隐形曼青的应助被追寻的微笑采纳,获得10
15秒前
沉默笑蓝发布了新的文献求助10
16秒前
16秒前
18秒前
cc2004bj发布了新的文献求助150
19秒前
20秒前
初景发布了新的文献求助10
20秒前
CipherSage的应助被乌龙茶采纳,获得10
21秒前
乐乐的应助被湫殇采纳,获得10
22秒前
FashionBoy的应助被xwx采纳,获得10
23秒前
学霸业的应助被树123采纳,获得10
24秒前
栗早完成签到 ,获得积分10
25秒前
25秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181767
求助须知:如何正确求助?哪些是违规求助? 9571480
关于积分的说明 21818225
捐赠科研通 7778030
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479598